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positron emission tomography with targeting of
64
Copper-asialofetuin complex in LEC rat
model of Wilson’s disease
Ralf Bahde1,2, Sorabh Kapoor1, Kuldeep K Bhargava3,4, Christopher J Palestro3,4, Sanjeev Gupta1
Marion Bessin Liver Research Center, Diabetes Center, Cancer Research Center, Departments of Medicine and
Pathology, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, and
Institute for Clinical and Translational Research, Albert Einstein College of Medicine, Bronx, NY, USA; 2Department
of Surgery, Hospital of The University of Muenster, Muenster, Germany; 3Division of Nuclear Medicine and Molecular Imaging, North Shore-Long Island Jewish Health System, New Hyde Park, NY, USA; 4Hofstra North Shore-LIJ
School of Medicine, Hempstead, NY, USA
1

Received July 10, 2014; Accepted August 2, 2014; Epub September 6, 2014; Published September 15, 2014
Abstract: Identification by molecular imaging of key processes in handling of transition state metals, such as copper (Cu), will be of considerable clinical value. For instance, the ability to diagnose Wilson’s disease with molecular
imaging by identifying copper excretion in an ATP7B-dependent manner will be very significant. To develop highly effective diagnostic approaches, we hypothesized that targeting of radiocopper via the asialoglycoprotein receptor will
be appropriate for positron emission tomography, and examined this approach in a rat model of Wilson’s disease.
After complexing 64Cu to asialofetuin we studied handling of this complex compared with 64Cu in healthy LEA rats
and diseased homozygous LEC rats lacking ATP7B and exhibiting hepatic copper toxicosis. We analyzed radiotracer
clearance from blood, organ uptake, and biliary excretion, including sixty minute dynamic positron emission tomography recordings. In LEA rats, 64Cu-asialofetuin was better cleared from blood followed by liver uptake and greater
biliary excretion than 64Cu. In LEC rats, 64Cu-asialofetuin activity cleared even more rapidly from blood followed by
greater uptake in liver, but neither 64Cu-asialofetuin nor 64Cu appeared in bile. Image analysis demonstrated rapid
visualization of liver after 64Cu-asialofetuin administration followed by decreased liver activity in LEA rats while liver
activity progressively increased in LEC rats. Image analysis resolved this difference in hepatic activity within one
hour. We concluded that 64Cu-asialofetuin complex was successfully targeted to the liver and radiocopper was then
excreted into bile in an ATP7B-dependent manner. Therefore, hepatic targeting of radiocopper will be appropriate for
improving molecular diagnosis and for developing drug/cell/gene therapies in Wilson’s disease.
Keywords: ATP7B, diagnosis, metal complex, positron emission tomography, radiocopper, therapy, Wilson’s disease

Introduction
In excessive amounts, transition-state metals,
such as copper (Cu), pose health hazards. Metals may accumulate via increased dietary intake or abnormal handling in the body. For instance, mutations in hepatobiliary Cu transporter gene, ATP7B, cause Wilson’s disease (WD)
[1], leading to Cu toxicosis and liver and brain
damage [2]. Early diagnosis of WD is important
because Cu may be removed by drugs and cell/
gene therapies [3-5]. The diagnosis of WD is

generally difficult without a high index of suspicion and in fact is often missed because of its
rarity (the prevalence of mutant ATP7B alleles is
only 1:30,000). Percutaneous liver biopsy for
Cu content measurement, the standard diagnostic procedure for WD, has the potential for
serious complications. Liver Cu content measurements, the availability of which is limited in
many clinical settings, may be confounded by
normal or near-normal Cu levels in early WD,
false negative results due to inadequate tissue
sampling, or difficulty in separating homozy-
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gous and heterozygous states. The alternative
of genetic diagnosis in WD may be hampered
by incomplete mapping of disease mutations in
ATP7B gene, which currently approach approximately 500 mutations, as well as lack of reliable
assays to establish the function of novel ATP7B
mutations. Similarly, understanding whether Cu
could be mobilized will be helpful for therapeutic development as well as monitoring treatment. Therefore, a molecular imaging technique capable of demonstrating ATP7B protein
function is highly clinically relevant.
Recently, we and others determined that positron emission tomography (PET) with 64Cu was
appropriate for molecular imaging in WD, as in
mutant rats or mice lacking ATP7B function [6,
7]. Multiple cellular mechanisms regulate hepatic Cu handling, including those involved in
intracellular entry, utilization and trafficking of
Cu [8]. Of these, intracellular transfer of Cu
atoms to ATP7B protein and then transport of
ATP7B-bound Cu to bile canaliculi constitute
key physiological steps in Cu excretion with
most relevance for molecular imaging in WD.
Previously, in an effort to overcome issues related to the ubiquitous distribution and uptake of
free 64Cu with gradual release, reuptake and rerelease from organs over many hours [9], we
utilized 64Cu-histidine [6, 10]. The Cu-histidine
complex has been extensively studied over several decades [11]. Although histidine has high
affinity for Cu, rapid entry and dissociation of
this complex in hepatocytes led to the prompt
appearance in bile of Cu in Long-Evans Agouti
(LEA) rats, where ATP7B function is normal [6,
10], while in Long-Evans Cinnamon (LEC) rats,
where ATP7B is non-functional, which is similar
to people with WD, Cu-histidine complex was
incorporated in liver but Cu did not appear in
bile [6, 10]. However, as 64Cu-histidine complex
too was widely distributed in tissues, we considered that hepatic targeting of Cu will be
superior for diagnostic applications of PET, and
also for evaluating the success of liver-directed
cell/gene therapy studies.
Here, we focused on receptor-mediated endocytosis, since unlike Cu uptake by Ctr1 which is
expressed in cells throughout the body [8], the
asialoglycoprotein receptor (ASGPR) is uniquely
expressed in hepatocytes [12]. Our hypothesis
was that the 64Cu-AF complex should have been
targeted to the liver followed by transfer in hepatocytes to ATP7B and then excretion into bile
538

(Figure 1). After delivering ligands to cytoplasmic endosomes, ASGPR recycles to the hepatocyte cell membrane [13]. Consequently, ASGPR
ligands were effective for hepatic targeting of
nucleic acids, proteins, synthetic compounds,
biomaterials, etc., including for imaging with
magnetic resonance, single photon emission
tomography, and other modalities [14-19]. Previously, one such ligand, asialofetuin (AF), was
effective for hepatic targeting of radiotracers,
and successfully identified ASGPR expression
in transplanted hepatocytes that were located
outside the liver [20]. In this investigation, we
describe a complex of 64Cu and AF, and its utilization for hepatic uptake and bile excretion
studies in LEA and LEC rats.
Material and methods
Chemicals
Reagent-grade chemicals and AF were purchased from Sigma Chemical Company (St. Louis,
MO).
64

Cu and 64Cu-AF complex

We purchased 64Cu chloride from MDS Nordion
(Catalog IPG-Cu-64; Ottawa, Canada), with specific activity of 962 MBq/µg. We added to 50 μg
AF in 500 µL 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, containing 50 mM dithiothereitol, 185-200 MBq
64
Cu for 15 min at room temperature. The 64CuAF complex was purified by passing through
Sep-Pak C18 cartridges (WAT023501, Waters
Corp., Milford, MA), which were pre-washed
with 10 mL ethanol and then 10 mL water as
previously described [6]. After injecting 64Cu-AF,
cartridges were washed with 5 mL water. We
eluted 64Cu-AF in 3 mL ethanol yielding 176190 MBq activity. Specific activity of 64Cu-AF
was 3.52-3.80 GBq per mg. Purity and stability
of 64Cu-AF complex was examined by instant
thin layer chromatography (ITLC) with acetone
as solvent. The mobile phase was analyzed by
dividing ITLC strips and measuring activity in
well counter. 64Cu-AF was ≥95% pure.
Animals
Animal Care and Use Committees and Radiation
Safety Committees at Albert Einstein College of
Medicine and Feinstein Institute of Medical
Research, North Shore - Long Island Jewish
Health System, approved the protocols. LEA
Am J Nucl Med Mol Imaging 2014;4(6):537-547
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Figure 1. Schematic representation of proposed hypothesis for imaging of ATP7B function with 64Cu-asialofetuin
(AF). After complexing of 64Cu and AF (Step 1), the complex should enter hepatocytes via asialoglycoprotein receptor
(ASGPR) (Step 2). The ASGPR-bound 64Cu-AF complex should be internalized in endosomes followed by dissociation
from ASGPR and breakdown of the complex with separation of 64Cu and AF (Step 3). ATP7B in cytoplasm should then
accept 64Cu (Step 4). Next, ATP7B should transport 64Cu into bile canaliculi, leading to intestinal excretion (Step 5).

and LEC rats, 8 to 12 weeks old and weighing
250-300 g, were from Special Animal Core of
Marion Bessin Liver Research Center. All animals were allowed pelleted food and water
throughout. Animals were genotyped by polymerase chain reaction (PCR) of genomic DNA
[21]. Hepatic ATP7B mRNA was shown by reverse transcription-PCR (RT-PCR) with RNA extracted by Trizol Reagent. Primers were: ATP7B:
5’-CCATCTCCAGTGATATCAGTG-3’ (forward); 5’CGCACAGCACACCATCAATGG-3’ (reverse); rat βactin: 5’-CCCTGGCTCCTAGCACCAT-3’ (forward)
and 5’-AGAGCCACCAATCCACACAGA-3’ (reverse). Only wild-type healthy LEA rats and LEC
rats homozygous for ATP7B mutation were
used for studies.

was injected intrasplenically under direct vision. We had validated in previous studies that
intrasplenic injection produces results similar
to to those obtained with tail vein injection [6].
Previous studies established that neither bile
cannulation nor bile collection altered excretion
of 64Cu or 64Cu-histidine complex.
Protocols for hepatic handling of 64Cu

We divided 12 LEA rats and 12 LEC rats into
groups of 3-4 rats each. Rats were anesthetized with ketamine and xylazine (Fort Dodge
Animal Health, Fort Dodge, Iowa) for all studies.
For imaging, anesthesia was continued with
inhaled isoflurane. Bile was cannulated with a
catheter by midline laparotomy, as previously
described [6], and then 3.7-5.5 MBq 64Cu-AF

For blood clearance of 64Cu-AF, we obtained
samples from tail-cut every 15 min for 1 h. Bile
was collected at 15 min intervals between 0-1
h after injection of 64Cu-AF. Bile flow rates were
1.8 ± 0.4 ml per hour. Liver, kidneys, spleen,
heart and lung samples were collected at sacrifice of animals. Total weights of organs were
measured. Tissue radioactivity was measured
simultaneously with decay correction. Organ
activity was normalized against heart muscle
for background, which was taken as zero activity, and then expressed on per gram basis followed by conversion to total organ weights, as
previously described [6]. To correlate loss of
hepatic 64Cu after 1 h in microPET images we
divided bile counts by liver plus bile counts.
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Figure 2. Characterization of animals. A. DNA PCR showing correct genotype of Atp7b alleles in healthy LEA rats
(single band of wild-type allele), heterozygous LEC+/- rats (bands for both wild-type and mutant alleles) and homozygous LEC-/- rats (single band of mutant allele). B. Shows no Atp7b mRNA in LEC-/- rats. C. Normal liver histology
in LEA rat. D. LEC rat with liver abnormalities, including bile duct proliferation, inflammatory cell infiltrates (straight
arrow) and megalonuclei (curved arrow).

For microPET, animals were spread supine and
imaging was centered on the upper abdomen.
Image acquisitions began with 350-650 keV
windows before injection of activity (R4 Scanner, Concorde MicroSystems, Knoxville, TN).
Sixty min dynamic PET recording was performed with 2 min frames. Image analysis incorporated isotope decay, scatter, dead-time and
arc corrections by ASIPro software (Siemens
Medical Solutions USA, Inc., Knoxville, TN). Hepatic regions of interest in equal volumes were
selected away from liver edge and diaphragm
to decrease respiratory artifacts. Standardized
uptake values (SUV) were plotted against time
and time-to-peak hepatic SUV (T-SUVmax) was
determined with linear regression for differences in 64Cu activity as previously established [6].

Results

Histological analysis

Data are expressed as means ± SEM. Analyses
used t-tests or ANOVA with SigmaStat (Systat
Inc., Point Richmond, California, USA). P values
<0.05 were considered significant.

After injection of 64Cu in LEA rats (n=3), activity
cleared gradually from the blood, Of the total
blood activity present at 15 min (100%), 90 ±
5%, 78 ± 3% and 76 ± 6% remained at 30, 45
and 60 min, respectively (Figure 3). 64Cu-AF
cleared significantly more rapidly (p<0.05) in
LEA rats (n=3), with 78 ± 0.5%, 66 ± 2% and 57
± 2% of the total blood activity at 15 min
remaining at 30, 45 and 60 min, respectively.
Twenty-five percent more activity was cleared
at 1-hour in LEA rats receiving 64Cu-AF than in
animals receiving 64Cu.
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Cryostat sections of 5 µm thickness were prepared from tissues frozen in methylbutane at
-80°C. Acetone-fixed sections were stained
with hematoxylin and eosin.
Statistical analysis

Genotyping
DNA PCR confirmed the presence of healthy
ATP7B gene copies in LEA rats and ATP7B
homozygous mutant alleles in LEC rats (Figure
2A). ATP7B mRNA was present in LEA rats, but
not in LEC rats (Figure 2B). Liver morphology
was normal in LEA rats, while in LEC rats,
changes characteristic of Cu toxicosis including
enlarged hepatocytes containing megalonuclei,
bile duct proliferation and cholangiofibrosis,
were present [4-6].
Blood clearance

Receptor-mediated targeting of radiocopper
after injection of 64Cu-AF, liver
activity decreased, and renal
and splenic activity increased
(p<0.05, ANOVA). Lung activity was unchanged. Of the
total activity in these four
organs, 74% was in the liver,
18% in the kidneys, 5% in the
spleen and 1.8% in the lungs.
In LEC rats injected with 64Cu
(n=3), there was significantly
more activity in the liver (2.2
± 0.4), kidneys,(3.2 ± 0.3),
and spleen (3.3 ± 0.4) (p<
0.05, ANOVA) than in LEA
rats. Lung activity (0.7%)
again was negligible. When
64
Cu-AF was injected liver
and spleen activity was even
higher, 2.7 ± 0.4 and 5 ± 1.3
times greater, respectively,
than in LEA rats (p<0.05,
ANOVA). Renal activity after
64
Cu-AF injection was similar
Figure 3. Radiotracer clearance from blood. A. Study design indicating serial
64
to that after 64Cu, 2.4 ± 0.8measurements were made 15, 30, 45 and 60 min after injection of Cu or
64
Cu-AF into LEA and LEC rats (n=3 each). B. Clearance of 64Cu-AF from blood
fold more than in LEA rats.
was greater than that of 64Cu in both LEA and LEC rats. Blood 64Cu clearance
Lung activity again was negliwas greater in LEC rats.
gible. Of the total activity in
these four organs, 82% was
64
Cu was cleared more rapidly from the blood in
in the liver, 12% was in the kidneys, 6% was in
LEC rats (n=3) than in LEA rats (n=3). Of total
the spleen and 0.4% was in the lungs.
blood activity present at 15 min (100%), 76 ±
Biliary excretion
5%, 63 ± 6% and 52 ± 8%, remained at 30, 45
and 60 min, significantly less than in LEA rats
Activity appeared in the bile of LEA rats within
(p<0.05, ANOVA). As with LEA rats, 64Cu-AF was
minutes after injection of both 64Cu and 64Cucleared from blood significantly more rapidly
AF (not shown). ITLC of bile samples confirmed
than 64Cu, with 68 ± 7%, 55 ± 5% and 42 ± 6%
presence of 64Cu in both groups indicating
of total blood activity present at 15 minutes,
intracellular dissociation of the 64Cu-AF comremaining at 30, 45 and 60 min, respectively
plex. In LEA rats (n=3), 1-hour after 64Cu injec(p<0.05, ANOVA). The difference in clearance of
64
tion, the fraction of bile activity constituted
Cu-AF and 64Cu at 1-hour in LEC rats was 65%
10.0 ± 1.5% of liver plus bile activity (Figure 5).
(p<0.05, ANOVA).
In LEA rats (n=3) injected with 64Cu-AF the fracOrgan distribution
tion of bile activity was 19.2 ± 1.0% (p<0.05,
t-test). In LEC rats, there was no detectable bile
We sampled excised organs 1-hour after radioactivity after injection of 64Cu or 64Cu-AF (n=3
tracer injection. In LEA rats (n=3), injected with
each).
64
Cu, most of the activity was in the liver, with
less activity in the kidneys and spleen, and minMicroPET analysis of ATP7B-dependent 64Cu
imal activity in the lungs (Figure 4). Of the total
excretion
activity in these four organs 82% was in the
Dynamic imaging after 64Cu-AF injection in LEC
liver, 15% was in the kidneys, 3% was in the
and LEA rats (n=3 each) was performed to
spleen and 1.6% was in the lungs. In contrast,
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ies directly comparing the distribution of AF complexes after
injection into a peripheral vein or
intrasplenically have not been
published. However, in one previous study, injection of radiolabeled AF complexes into the tail
vein of rats [23] resulted in
hepatic accumulation of 100%
activity over approximately 5
minutes, which was similar to
our results after intrasplenic
injection of 64Cu-AF in healthy
rats, as further discussed below.
The faster clearance from blood,
more rapid uptake in liver, and
greater activity in bile of healthy
LEA rats given 64Cu-AF versus
64
Cu indicated that the complex
delivered greater amounts of
64
Cu to hepatocytes. The appearFigure 4. Incorporation of 64Cu-AF in organs. A. Study design indicating
ance of activity in bile was in
organ distribution of activity was analyzed 1 hour after injection of 64Cu
agreement with the proposed
or 64Cu-AF into LEA and LEC rats (n=3 each). B. Chart shows activity in
intracellular processing of the
4
cpm x 10 per organ. More activity accumulated in the liver of LEC rats
64
Cu-AF complex, leading to
compared with LEA rats, which reflected continued uptake of radiotracbreakdown of the complex,
ers in the liver in the likely absence of biliary excretion. Moreover, liver
activity in LEC rats was even higher after 64Cu-AF, which confirmed supetransfer of dissociated 64Cu to
rior hepatic targeting. By contrast, liver activity decreased more in LEA
ATP7B protein, and then excrerats, suggesting greater clearance through biliary excretion. Asterisks
tion in bile of LEA rats (Figure 1).
indicate p<0.05 versus controls.
By contrast, while 64Cu-AF
entered the liver in LEC rats,
64
determine changes in hepatic activity over time
Cu did not appear in bile, which confirms that
ATP7B was required for excreting 64Cu dissoci(Figure 6). In LEA rats, hepatic activity increased
ated from 64Cu-AF complex. These findings
rapidly and peaked within 5 min (T-SUVmax),
should fulfil requirements for diagnosing presdecreasing by 39% at 1-hour. In contrast,
ence of ATP7B function in healthy and WD
hepatic activity increased in the livers of LEC
states. As humans with WD share an inability to
rats throughout the 1-hour period. At one hour,
excrete Cu in bile, the principle of using targethere was nearly twice as much activity in the
table Cu complexes should be suitable for
livers of LEC rats compared to the livers of LEA
molecular imaging to demonstrate presence or
rats (p<0.05, t-test).
absence of ATP7B function in people. As biliary
64
Discussion
Cu excretion in heterozygous LEC rats was
similar to healthy LEA rats [6], molecular imagThese results indicate that the 64Cu-AF complex
ing should be helpful for separating healthy
was successfully targeted to hepatocytes folindividuals and heterozygous carriers of WD
lowed by intracellular dissociation of the comalleles from those with WD and absence of
plex and then excretion of thus freed up radioATP7B function. This fulfills an important clinicopper into bile. We injected radiotracers
cal need, i.e., the recognition of healthy and disintrasplenically under direct vision to ensure
eased members in kindreds with newly diagtheir delivery. Previously, we verified that
nosed index cases of WD. It is noteworthy that
liver injury or inflammation did not affect ATP7B
peripheral intravenous or intrasplenic injection
function [6], therefore, it will be possible to disof radiotracers produced similar distributions in
tinguish between normal and abnormal Cu
the body [6, 22], although those studies did not
transport function of ATP7B from people with
include AF complexes. To our knowledge, stud542
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The biology of ASGPR-mediated
endocytosis has long been studied because of its considerable
physiological and pathophysiological significance [12]. In particular, the abundant cell surface
expression of ASGPR is characteristic of hepatocytes, and this
receptor is not displayed on any
other cell type of the body. Consequently, ASGPR came to the
attention of investigators for
hepatic targeting. Multiple natural and synthetic ASGPR ligands
have now been reported for targeting DNA, RNA, drugs, vectors,
biomaterials, and imaging agents, to liver [14-19]. The latter
include tagged synthetic compounds, proteins and other molecules or particles for PET, single
photon emission computed tomography and magnetic resonance [14, 15, 19]. The specific
Figure 5. Biliary excretion of 64Cu. A. Schematic indicating bile was coladvantages of ASGPR include
lected for 60 min starting immediately before injection of 64Cu or 64Cu-AF
highly efficient hepatic uptake of
into LEA and LEC rats (n=3 each). Liver was weighed and sampled for
ASGPR ligands, e.g., in a rat
activity after 1 hour. B. Chart showing activity was excreted in bile of LEA
study, 63% of the intravenous
rats but not of LEC rats. In LEA rats 10±1.5% of liver plus bile activity
was in bile after 64Cu, whereas 19.2±1% activity was in bile after 64Cu-AF,
dose of radioiodinated asialoorop<0.05. This indicated superior hepatic targeting of 64Cu-AF, as well as
somucoid was in the liver at 10
dissociation of the complex in hepatocytes, and transfer of 64Cu ions to
minutes [13]. The ASGPR-bound
Atp7b for biliary excretion.
ligands are rapidly internalized
from cell surface to acidic endoother, nonwilsonian types of acute or chronic
somes in cytoplasm [24], where ASGPR dissociliver diseases, which also is clinically relevant.
ates from ligands, and returns to the cell membrane to resume receptor functions. IntraIn hepatocytes, ATP7B is expressed, but ATP7A,
cellularly-delivered ASGPR ligands, however,
which transports Cu into blood, is not [8]. In
continue separately along their independent
cells expressing ATP7A, which includes virtually
fates. In this way, intracellular delivery of 64Cuall tissues with the exception of the kidneys
AF by ASGPR was more efficient, and should
where both ATP7A and ATP7B are expressed,
have led to dissociation first of 64Cu-AF from
exchanges of Cu between intracellular and exASGPR and second of 64Cu from AF due to protracellular pools after entry into cells via Ctr1,
teolytic and hydrolytic processes that are typiinevitably lead to complex kinetics of Cu reutical of acidic endosomes, before 64Cu would
lization. However, since Cu is excreted out of
have been transferred to ATP7B in LEA rats and
the body only by hepatic ATP7B, diagnostic
not in LEC rats (Figure 1).
applications by the proposed approach of
The coordination of 64Cu with histidine residues
molecular imaging in WD will not be affected by
may have occurred in the 64Cu-AF complex,
these processes, as was the case in our animal
since histidine is a very strong metal coordinatstudies. This should again be the case so far as
ing ligand, probably with at least three metaldevelopment is concerned of drugs and cell or
binding sites, and this property of histidine has
gene therapy aimed at increasing Cu excretion
been highly characterized [11]. Under physioin bile [6].
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cies has been found [25]. Alternatively, histidine-bound Cu may
also exist in (1+) state [26]. Recently, x-ray structure of Cu-histidine crystals showed coordination by two histidine species [27].
As buffers, e.g., HEPES in our studies, do not complex Cu to any significant degree [28], the potential
of this buffer causing interference
in studies can be confidently excluded. Of note, coordination of Cu
by histidine is quite potent, such
that Cu may be selectively enriched
from complex mixtures by histidine
columns, and histidine-bound Cu is
not readily transferred to circulating proteins, e.g., albumin, which
may otherwise enhance cellular Cu
uptake [29]. By contrast, free Cu
binds to albumin with high affinity,
which interferes with its cellular
uptake [30]. These advantages of
histidine-Cu complex were beneficial in the treatment of people with
Menkes’ disease, which is due to
ATP7A mutations with severe Cu
deficiency [11] and proved useful
for diagnostic PET in WD [6].
Nevertheless, we should emphasize that the structure of 64Cu-AF
complex is unknown, and requires
further investigation.
More rapid clearance of blood
activity after 64Cu-AF compared
with that of 64Cu, along with hepatic uptake in LEA, as well as in LEC
rats, is in agreement with the entry
64
of this complex in an exchangeable
Figure 6. MicroPET for hepatic Cu activity. A. Protocol indicating dyCu pool. More 64Cu-AF cleared from
namic imaging was done for 60 min after injection of 64Cu-AF into LEA
and LEC rats (n=3 each). B. Representative sequential PET images at
blood in LEC rats. Image analysis of
early and late times from LEA and LEC rats after 64Cu-AF was injected
LEA rats receiving 64Cu-AF showed
into spleen (arrows, Spl). Note activity was in only liver and not kidneys,
that the TSUVMax of less than five
which are outlined after injection of 64Cu (not shown). Moreover, more
minutes was shorter than that of
activity accumulated in liver of LEC rats from start to end. C. Hepatic
13 ± 2 minutes after 64Cu-histidine
SUV generated by linear regression over 1 hour after 64Cu-AF. In LEA
rats, activity rapidly peaked, which indicated early hepatic uptake of
in our previous study [6]. The blood
64
Cu-AF, and decreased subsequently. In LEC rats, hepatic activity inclearance of 64Cu-AF complex was
creased continually in agreement with the lack of biliary 64Cu excretion.
greater in LEC rats, which was simiAsterisks indicate p<0.05.
lar to better clearance in LEC rats
of 64Cu instilled into stomach [31],
logical conditions, histidine-bound Cu may exist
and also of intravenously administered 64Cuin (2+) state with two histidine species [11],
histidine complex [6]. In the case of 64Cu, this
although this state may change under freezing
was likely in agreement with the possibility of
conditions, where Cu2+ with four histidine spegreater Cu uptake capacity in LEC rats, perhaps
544
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as an adaptive mechanism to deal with persistently high Cu levels in blood. In the case of
64
Cu-AF, image analysis showed more gradual
accumulation of activity in the liver of LEC rats
compared with LEA rats (see Figure 6), which
might have reflected differences in ASGPR
expression levels in these animals. For instance, ASGPR expression level can decrease in
response to inflammatory cytokines or liver
injury, as noted during onset of fatty liver disease or alcoholic liver disease [32, 33].
However, it should be noted that for molecular
imaging with this proposed approach, only
trace amounts of 64Cu-AF are required, which
should need very little ASGPR for binding and
internalization in hepatocytes. This was substantiated by necessary hepatic incorporation
of 64Cu-AF for successful imaging in LEC rats
despite the presence of significant Cu toxicosis
and liver injury.
Subsequently, biliary excretion of 64Cu in ATP7B-dependent manner, i.e., in LEA rats, but not
in LEC rats, indicated that the 64Cu-AF complex
was broken down in hepatocytes and 64Cu was
indeed available for transfer to ATP7B in LEA
rats. Since bile 64Cu excretion after 64Cu-AF was
significantly greater than that after 64Cu alone,
we surmise that this complex improves discriminant value of the molecular imaging test for
the diagnosis of WD in LEC rats. Therefore, use
of the hepatic SUVmax parameter with image
analysis over 30-60 min after 64Cu-AF will be
useful for distinguishing between WD and
healthy states. Previously, the specificity of
64
Cu-histidine complex for imaging in WD was
verified by reconstitution of the molecular
defect in LEC rats after liver repopulation with
healthy LEA rat hepatocytes [6]. It should be
noted that, based on dosimetric estimates in
prior studies, administration of 64Cu-AF for PET
is feasible in people [7]. Such a diagnostic test
will be helpful for therapeutic development in
WD, including for cell and gene therapy applications, as discussed elsewhere [34].
Conclusions
We studied a 64Cu-AF complex for molecular
imaging of ATP7B-dependent biliary Cu excretion. Compared with 64Cu, the 64Cu-AF complex
was more efficiently cleared from blood and
was incorporated in the liver in both healthy
and mutant rats lacking ATP7B function, which
is characteristic of WD. This hepatic targeting
545

of 64Cu-AF complex resulted in greater excretion of activity in the bile of healthy rats compared with that of 64Cu alone. In contrast, no
activity was present in the bile of mutant rats
deficient in ATP7B function after injection of
either 64Cu or 64Cu-AF. This indicates that after
hepatic targeting, the 64Cu-AF complex broke
down in hepatocytes with transfer of 64Cu to
ATP7B, and biliary excretion in ATP7B-dependent manner. Therefore, hepatic targeting
of 64Cu-AF complex was successful for molecular imaging of ATP7B function in healthy and
WD states. This will offer opportunities for further diagnostic and therapeutic developments
in WD.
Acknowledgements
Supported in part by NIH grants, R01 DK088561, R01 DK071111, P30 DK41296, P30
CA013330, and DFG grant BA 3609/1-1, Germany (RB). MicroPET was performed with E.
Fine, MD, and W. Koba in Donald M. Blaufox
Laboratory, Albert Einstein College of Medicine.
Published in part as abstracts: Bhargava KK, et
al. J Nucl Med 2012; 53 (suppl 1): (P) 338; and
Bahde R, et al. Hepatology 2012; 56: 826A.
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Sanjeev Gupta, Albert Einstein College of Medicine, Ullmann Building,
Room 625, 1300 Morris Park Avenue, Bronx, NY
10461, USA. Tel: 718-430-3309; Fax: 718-4308975; E-mail: sanjeev.gupta@einstein.yu.edu

References
[1]

[2]
[3]

[4]

Bull PC, Thomas GR, Rommens JM, Forbes JR,
Cox DW. The Wilson disease gene is a putative
copper transporting P-type ATPase similar to
the Menkes gene. Nat Genet 1993; 5: 327-37.
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky
ML. Wilson’s disease. Lancet 2007; 369: 397408.
Irani AN, Malhi H, Slehria S, Gorla GR, Volenberg I, Schilsky ML, Gupta S. Correction of liver
disease following transplantation of normal
hepatocytes in LEC rats modeling Wilson’s disease. Mol Ther 2001; 3: 302-309.
Malhi H, Joseph B, Schilsky ML, Gupta S.
Mechanisms to repopulate liver with healthy
donor cells for phenotypic correction in the
LEC rat model of Wilson disease. Regen Med
2008; 2: 165-173.

Am J Nucl Med Mol Imaging 2014;4(6):537-547

Receptor-mediated targeting of radiocopper
[5]

[6]

[7]

[8]
[9]
[10]

[11]
[12]
[13]

[14]

[15]

[16]

[17]

546

Joseph B, Kapoor S, Schilsky ML, Gupta S. Bile
salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology 2009; 49:
1616-24.
Bahde R, Kapoor S, Bhargava KK, Schilsky ML,
Palestro CJ, Gupta S. Positron emission tomography with copper-64-histidine for nonivasive
diagnosis of biliary copper excretion in LEC rat
model of Wilson’s disease. J Nucl Med 2012;
53: 961-8
Peng F, Lutsenko S, Sun X, Muzik O. Positron
emission tomography of copper metabolism in
the Atp7b (-/-) knock-out mouse model of Wilson‘s disease. Mol Imaging Biol 2012; 14: 708.
Kim BE, Nevitt T, Thiele DJ. Mechanisms for
copper acquisition, distribution and regulation.
Nat Chem Biol 2008; 4: 176-85.
Dunn MA, Green MH, Leach RM Jr. Kinetics of
copper metabolism in rats: a compartmental
model. Am J Physiol 1991; 261: E115-125.
Schilsky ML, Irani AN, Gorla GR, Volenberg I,
Gupta S. Biliary copper excretion capacity in
intact animals: correlation between ATP7B
gene function, hepatic mass and copper excretion. J Biochem Mol Toxicol 2000; 14: 210214.
Deschamps P, Kulkarni PP, Gautam-Basak M,
Sarkar B. The saga of copper(II)-L-histidine. Coordination Chem Rev 2005; 249: 895-909.
Stockert RJ. The asialoglycoprotein receptor:
relationships between structure, function, and
expression. Physiol Rev 1995; 75: 591-609.
Yang DY, Ouyang CH, Lu FG, Liu XW, Huang LQ.
Targeting specificity and pharmacokinetics of
asialoorosomucoid, a specific ligand for asialglycoprotein receptor on hepatocyte. J Dig Dis
2007; 8: 89-95.
Yang W, Mou T, Peng C, Wu Z, Zhang X, Li F, Ma
Y. Fluorine-18 labeled galactosyl-neoglycoalbumin for imaging the hepatic asialoglycoprotein
receptor. Bioorg Med Chem 2009; 17: 7510-6.
Yang W, Mou T, Shao G, Wang F, Zhang X, Liu B.
Copolymer-based hepatocyte asialoglycoprotein receptor targeting agent for SPECT. J Nucl
Med 2011; 52: 978-85
McMahon A, O’Neill MJ, Gomez E, Donohue R,
Forde D, Darcy R, O’Driscoll CM. Targeted gene
delivery to hepatocytes with galactosylated
amphiphilic cyclodextrins. J Pharm Pharmacol
2012; 64: 1063-73.
Ma J, Huang C, Yao X, Shi C, Sun L, Yuan L, Lei
P, Zhu H, Liu H, Wu X, Ning Q, Zhou C, Shen G.
Inhibition of hepatitis B virus and induction of
hepatoma cell apoptosis by ASGPR-directed
delivery of shRNAs. PLoS One 2012; 7:
e46096.

[18] Zhong Y, Yang W, Sun H, Cheng R, Meng F,
Deng C, Zhong Z. Ligand-directed reductionsensitive shell-sheddable biodegradable micelles actively deliver Doxorubicin into the nuclei of target cancer cells. Biomacromolecules
2013; 14: 3723-30.
[19] Ketkar-Atre A, Struys T, Dresselaers T, Hodenius M, Mannaerts I, Ni Y, Lambrichts I, Van
Grunsven LA, De Cuyper M, Himmelreich U. In
vivo hepatocyte MR imaging using lactose
functionalized magnetoliposomes. Biomaterials 2014; 35: 1015-24.
[20] Nagata H, Nishitai R, Shirota C, Zhang JL, Koch
CA, Cai J, Awwad M, Schuurman HJ, Christians
U, Abe M, Baranowska-Kortylewicz J, Platt JL,
Fox IJ. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology 2007; 132: 321-9.
[21] Ahmed S, Deng J, Borjigin J. A new strain of rat
for functional analysis for PINA. Brain Res Mol
Brain Res 2005; 137: 63-69.
[22] Joseph B, Bhargava KK, Trunco G, Kumaran V,
Palestro CJ, Gupta S. Regulation of hepatobiliary transport activity and noninvasive identification of cytokine-dependent liver inflammation. J Nucl Med 2005; 46: 146-52.
[23] Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ,
Enke CA, Baranowska-Kortylewicz J. Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjug Chem 2003; 14:
997-1006.
[24] Onizuka T, Shimizu H, Moriwaki Y, Nakano T,
Kanai S, Shimada I, Takahashi H. NMR study
of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes. FEBS J 2012; 279: 2645-56.
[25] Basosi R, Valensin G, Gaggelli E, Froncisz W,
Pasenkiewicz-Gierula M, Antholine WE, Hyde
JS. Multifrequency ESR of Cu(II)-(His), (His =
Histidine). 1. Immobile Phase. Inorg Chem
1986; 25: 3006-3010.
[26] Venelinov T, Arpadjan S, Karadjova I, Beattie J.
Properties of the copper(II)-histidine complex
obtained after dialysis of human plasma with
histidine. Acta Pharm 2006; 56: 105-12.
[27] Deschamps P, Kulkarni PP, Sarkar B. X-ray
structure of physiological copper(II)-bis(l-histidinato) complex. Inorg Chem 2004; 43: 33383340
[28] Vasconcelos MTSD, Almeida CMR. Electrochemical study of proton ionisation, copper(II)
complexation and surfactant properties of piperazine-N-N’-bis[2-hydroxypropanesulfonic
acid] pH buffer. Comparison with other N-substituted aminosulfonic acids pH buffers. Anal
Chim Acta 1998; 369: 115-122.
[29] Bingham MJ, McArdle HJ. A comparison of copper uptake by liver plasma membrane vesicles

Am J Nucl Med Mol Imaging 2014;4(6):537-547

Receptor-mediated targeting of radiocopper
and uptake by isolated cultured rat hepatocytes. Hepatology 1994; 20: 1024-31.
[30] McArdle HJ, Guthrie JR, Ackland ML, Danks
DM. Albumin has no role in the uptake of copper by human fibroblasts. J Inorg Biochem
1987; 31: 123-31.
[31] Bissig KD, Honer M, Zimmermann K, Summer
KH, Solioz M. Whole animal copper flux assessed by positron emission tomography in
the Long-Evans cinnamon rat - a feasibility
study. Biometals 2005; 18: 83-88.
[32] Treichel U, Paietta E, Poralla T, Meyer zum
Büschenfelde KH, Stockert RJ. Effects of cytokines on synthesis and function of the hepatic
asialoglycoprotein receptor. J Cell Physiol
1994; 158: 527-34.

[33] Casey CA, McVicker BL, Donohue TM, McFarland MA, Wiegert RL, Nanji A, Liver asialoglycoprotein receptor levels correlate with severity
of alcoholic liver damage in rats. J Appl Physiol
2004; 96: 76-80.
[34] Gupta S. Cell therapy to remove excess copper
in Wilson’s disease. Ann N Y Acad Sci 2014;
1315: 70-80.

547

Am J Nucl Med Mol Imaging 2014;4(6):537-547

